AKRO
Price
$54.28
Change
+$0.34 (+0.63%)
Updated
Jun 6 closing price
Capitalization
4.31B
62 days until earnings call
IDYA
Price
$21.73
Change
+$0.63 (+2.99%)
Updated
Jun 6 closing price
Capitalization
1.9B
66 days until earnings call
Interact to see
Advertisement

AKRO vs IDYA

Header iconAKRO vs IDYA Comparison
Open Charts AKRO vs IDYABanner chart's image
Akero Therapeutics
Price$54.28
Change+$0.34 (+0.63%)
Volume$1.47M
Capitalization4.31B
IDEAYA Biosciences
Price$21.73
Change+$0.63 (+2.99%)
Volume$789.21K
Capitalization1.9B
AKRO vs IDYA Comparison Chart
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. IDYA commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Buy and IDYA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (AKRO: $54.28 vs. IDYA: $21.73)
Brand notoriety: AKRO and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 88% vs. IDYA: 52%
Market capitalization -- AKRO: $4.31B vs. IDYA: $1.9B
AKRO [@Biotechnology] is valued at $4.31B. IDYA’s [@Biotechnology] market capitalization is $1.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • AKRO’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, AKRO is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 6 TA indicator(s) are bullish while IDYA’s TA Score has 6 bullish TA indicator(s).

  • AKRO’s TA Score: 6 bullish, 4 bearish.
  • IDYA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both AKRO and IDYA are a good buy in the short-term.

Price Growth

AKRO (@Biotechnology) experienced а +9.33% price change this week, while IDYA (@Biotechnology) price change was +9.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

AKRO is expected to report earnings on Aug 08, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKRO($4.31B) has a higher market cap than IDYA($1.9B). AKRO YTD gains are higher at: 95.111 vs. IDYA (-15.447). AKRO has higher annual earnings (EBITDA): -247.37M vs. IDYA (-356.46M). AKRO has more cash in the bank: 743M vs. IDYA (693M). IDYA has less debt than AKRO: IDYA (26M) vs AKRO (36.5M). IDYA has higher revenues than AKRO: IDYA (7M) vs AKRO (0).
AKROIDYAAKRO / IDYA
Capitalization4.31B1.9B226%
EBITDA-247.37M-356.46M69%
Gain YTD95.111-15.447-616%
P/E RatioN/AN/A-
Revenue07M-
Total Cash743M693M107%
Total Debt36.5M26M140%
FUNDAMENTALS RATINGS
AKRO vs IDYA: Fundamental Ratings
AKRO
IDYA
OUTLOOK RATING
1..100
2522
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
62
Fair valued
PROFIT vs RISK RATING
1..100
5265
SMR RATING
1..100
9145
PRICE GROWTH RATING
1..100
3654
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKRO's Valuation (45) in the null industry is in the same range as IDYA (62). This means that AKRO’s stock grew similarly to IDYA’s over the last 12 months.

AKRO's Profit vs Risk Rating (52) in the null industry is in the same range as IDYA (65). This means that AKRO’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's SMR Rating (45) in the null industry is somewhat better than the same rating for AKRO (91). This means that IDYA’s stock grew somewhat faster than AKRO’s over the last 12 months.

AKRO's Price Growth Rating (36) in the null industry is in the same range as IDYA (54). This means that AKRO’s stock grew similarly to IDYA’s over the last 12 months.

AKRO's P/E Growth Rating (100) in the null industry is in the same range as IDYA (100). This means that AKRO’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKROIDYA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
59%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 5 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
84%
Bearish Trend 3 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
70%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QDEF72.820.51
+0.71%
FlexShares Quality Dividend Defensv ETF
KTEC16.150.03
+0.19%
KraneShares Hang Seng TECH ETF
TINT29.26N/A
N/A
ProShares Smart Materials ETF
IBTH22.30-0.06
-0.27%
iShares iBonds Dec 2027 Term Tr ETF
MPA10.77-0.06
-0.55%
Blackrock Muniyield Pennsylvania Quality Fund

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+0.63%
ETNB - AKRO
60%
Loosely correlated
+2.91%
SLS - AKRO
41%
Loosely correlated
-1.23%
TRDA - AKRO
40%
Loosely correlated
+2.46%
IDYA - AKRO
39%
Loosely correlated
+2.99%
VTYX - AKRO
38%
Loosely correlated
+9.33%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with CGON. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+2.99%
CGON - IDYA
60%
Loosely correlated
+1.05%
IMNM - IDYA
59%
Loosely correlated
+0.11%
CRNX - IDYA
57%
Loosely correlated
+2.13%
XENE - IDYA
55%
Loosely correlated
+2.96%
KRYS - IDYA
55%
Loosely correlated
+3.26%
More